3880-78-2

Usage

Uses

Used in Pharmaceutical Research:
2-AMINO-7-METHOXYTETRALIN HCL is used as a research compound for studying neurotransmitter systems and their interactions with nerve receptors in the brain. This is due to its potential therapeutic applications in the development of new drugs targeting these systems.
Used in Neurotransmitter Studies:
2-AMINO-7-METHOXYTETRALIN HCL is used as a ligand in the investigation of aminergic neurotransmission, which is crucial for understanding the mechanisms of various neurological disorders and the development of treatments for them.
Used in Drug Development:
2-AMINO-7-METHOXYTETRALIN HCL is used as a lead compound in the design and synthesis of new drugs that could potentially modulate neurotransmitter activity, offering novel therapeutic options for the treatment of neurological and psychiatric conditions.

InChI:InChI=1S/C11H15NO.ClH/c1-13-11-5-3-8-2-4-10(12)6-9(8)7-11;/h3,5,7,10H,2,4,6,12H2,1H3;1H

Upstream product

• 4133-34-0 7-methoxyl-2-tetralone 
• 83343-23-1 N-benzyl-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine 

Downstream Products

• 194785-79-0 7-hydroxy-1,2,3,4-tetrahydro-2-naphthylamine hydrobromide 
• 4003-89-8 2-amino-7-methoxy-1,2,3,4-tetrahydronaphthalene 
• 121251-89-6 (R)-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine (S)-mandelate 
• 1274816-90-8 N-[(2R)-7-((2-[(cyclopropylcarbonyl)amino]pyridin-4-yl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl]-3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzamide 
• 1274817-11-6 N-[(2S)-7-((2-[(cyclopropylcarbonyl)amino]pyridin-4-yl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl]-3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzamide hydrochloride 
• 121251-88-5 (S)-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine (S)-mandelate 
• 220640-10-8 (7R)-7-amino-5,6,7,8-tetrahydronaphthalen-2-ol hydrobromide 
• 121216-43-1 (2R)-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine 
• 121216-42-0 (2S)-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine 
• 194785-79-0 (7S)-7-amino-5,6,7,8-tetrahydronaphthalen-2-ol hydrobromide 

Relevant academic research and scientific papers

Design and optimization of potent and orally bioavailable tetrahydronaphthalene raf inhibitors

Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.

PREPARATION OF AMINOTETRALIN COMPOUNDS

The present invention relates to synthetic processes for preparation of aminotetralin compounds with kinase inhibitory activity. The invention also provides synthetic intermediates useful in the processes of the invention.

PROCESS FOR PREPARATION OF 2-AMINOTETRALIN DERIVATIVES AND INTERMEDIATES THEREOF

The present invention is to efficiently and simply prepare an optically active 7-substituted-2-aminotetralin with industrial advantage. In the process, a 7-substituted-2-tetralone or its bisulfite adduct is reduced with a microorganism to an optically active 7-substituted-2-tetralol. Then, a sulfonyl group is introduced to the hydroxy group to form an optically active 7-substituted-2-sulfonyloxytetralin. Then, with inversion of the configuration, a nitrogen substituent is introduced using a nitrogen nucleophile to form an optically active 2,7-substituted tetralin. Furthermore, if necessary, the nitrogen substituent is converted into a non-substituted amino group. Thus, an optically active 7-substituted-2-aminotetralin or its salt is prepared.

Enzymatic process for the preparation of optically active tetralin derivatives

The present invention relates to an enzymatic process for the preparation of optically active tetrahydro-2-naphthoic acids from the corresponding racemic esters by reaction with a lipase.

Process for the preparation of phenylethanolaminotetralins

A process for the preparation of phenylethanolaminotetralins of formula STR1 wherein X is hydrogen, a halogen, a trifluoromethyl or a lower alkyl group and R° is hydrogen or a methyl group substituted by a carboxy or a lower carbalkoxy group, which compri

Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them

Aryloxypropanolaminotetralins with beta-antagonist activity of the formula STR1 wherein R is hydrogen, hydroxy or methoxy and Ar is an optionally substituted aromatic or heteroaromatic group, in optically active or inactive form as well as their acid addition salts are described.A process for their preparation and pharmaceutical compositions containing the compounds of formula (i) or their pharmaceutically acceptable acid addition salts, are also described.